Recombinant Bacteria for Glucose-Responsive Insulin Secretion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diabetes mellitus, particularly Type 1 and Type 2, are not ideal as they often come with short-term effectiveness and numerous side effects, and there is a need for a more sustainable method to control blood glucose and triglyceride levels to reduce complications such as cardiovascular disease, retinopathy, nephropathy, and neuropathy.
Innovation Solution
A recombinant cell derived from an enteric or commensal bacterium, engineered to express a signal sequence such as GLP-1, PDX-1, or GLP-2, which regulates the expression of a target nucleic acid to reprogram intestinal cells into glucose-responsive insulin-secreting cells, thereby reducing the need for exogenous insulin and improving glycemic control.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for diabetes mellitus are used, then blood glucose levels can be controlled, but numerous side effects occur and effectiveness is limited to short-term
Solution Approach 1:
The patent uses engineered commensal bacteria as an intermediary delivery system to administer therapeutic peptides (such as GLP-1, PDX-1, or other insulinotropic agents) directly to the intestinal epithelium. This mediator approach allows controlled local delivery of active compounds that stimulate endogenous insulin production, thereby achieving glucose control while minimizing systemic side effects associated with conventional insulin therapy.
Solution Approach 2:
The treatment enables the patient's own body to produce insulin through stimulation of intestinal L-cells and pancreatic beta cells by the delivered peptides. Rather than relying on exogenous insulin administration, the system activates the body's endogenous insulin production mechanisms, creating a self-regulating glucose control system that adapts to the patient's metabolic needs.
2Productivity
If exogenous insulin is administered, then blood glucose levels decrease, but the need for continuous therapeutic intervention remains
Solution Approach 1:
The engineered bacteria are administered in advance to colonize the intestine and establish a persistent presence in the gastrointestinal tract. This preliminary colonization ensures continuous local production and secretion of insulinotropic peptides, creating a sustained therapeutic effect that eliminates the need for repeated external interventions and provides long-term glycemic control.
Solution Approach 2:
The commensal bacteria continuously reside in the intestine and persistently secrete therapeutic peptides that stimulate endogenous insulin production. This continuous local action ensures sustained glucose regulation without interruption, replacing the discontinuous nature of conventional insulin injections with a constant, self-renewing therapeutic presence.
3Speed
If conventional diabetes treatments are used, then immediate glucose control is achieved, but long-term complications such as cardiovascular disease and neuropathy still develop
Solution Approach 1:
The therapeutic peptides are delivered locally to the intestinal epithelium and act specifically at the site of absorption and pancreatic innervation. This localized delivery ensures rapid onset of action by directly stimulating intestinal L-cells and vagal pathways, while simultaneously providing sustained endogenous insulin production that addresses long-term glucose regulation and complication prevention.
Solution Approach 2:
The system combines the rapid-acting benefits of incretin-based therapy with the sustained effects of endogenous insulin production. By merging the quick response of GLP-1 receptor activation with the ongoing stimulation of beta-cell function, the treatment achieves both immediate glucose control and long-term protection against diabetic complications.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach effectively lowers blood glucose levels, reduces the need for therapeutic insulin administration, and promotes the formation of insulin-secreting cells in the intestine, offering a potential long-term solution for diabetes management with minimal side effects.
Implementation Method 1
the signal sequence regulates signal-dependent expression of a target nucleic acid in a host
Implementation Method 2
the target nucleic acid encodes a mammalian factor that is capable of reprogramming a first cell of the host into a second cell
Implementation Method 3
GLP-1, PDX-1, or GLP-2, which regulates the expression of a target nucleic acid to reprogram intestinal cells into glucose-responsive insulin-secreting cells
Implementation Method 4
reprogram a first cell of the host into a second cell... glucose-responsive insulin-secreting cells
Data Source
AI summary
Recombinant cells and methods are provided that relate to the use of isolated, engineered recombinant cells to directly or indirectly treat diseases or disorders in a mammalian host such as endocrine, gastrointestinal or autoimmune disorders. A recombinant cell is provided that comprises a signal sequence and a promoter, wherein: the signal sequence is capable of regulating signal-dependent expression of a target nucleic acid in a host or is capable of regulating signal-dependent expression of a target nucleic acid in response to an environmental stimulus, the cell is derived from an enteric or a commensal bacterium, and the target nucleic acid encodes a mammalian factor that promotes normal functioning of a physiological process in the host or is effective in preventing onset, establishment, or spread of a non-infectious disease in the host. The recombinant cell is administered to the host to treat the disease or disorder.